PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth of 4.31% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
8.25%
EBIT growth above 1.5x AVXL's 4.64%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
8.25%
Operating income growth above 1.5x AVXL's 4.64%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
12.55%
Net income growth comparable to AVXL's 13.94%. Walter Schloss might see both following similar market or cost trajectories.
15.52%
EPS growth at 75-90% of AVXL's 17.65%. Bill Ackman would push for improved profitability or share repurchases to catch up.
15.52%
Diluted EPS growth at 75-90% of AVXL's 17.65%. Bill Ackman would expect further improvements in net income or share count reduction.
3.21%
Share count expansion well above AVXL's 3.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
3.21%
Diluted share count expanding well above AVXL's 3.28%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth above 1.5x AVXL's 9.85%. David Dodd would confirm a clear edge in underlying cash generation.
18.52%
FCF growth above 1.5x AVXL's 9.85%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
77.11%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
-27.06%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
72.83%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
70.62%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
-36.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.68%
Below 50% of AVXL's 486.07%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-48.78%
Negative 5Y equity/share growth while AVXL is at 247.84%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-45.28%
Negative 3Y equity/share growth while AVXL is at 334.55%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AVXL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-40.17%
We cut SG&A while AVXL invests at 12.67%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.